TipRanks
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
US Market
CTNM
Contineum Therapeutics, Inc. Class A
RESEARCH TOOLSreports
Want to see CTNM full AI Analyst Report?

Contineum Therapeutics, Inc. Class A (CTNM) Stock News & Sentiment

228 Followers
Contineum: Hold Rating Reiterated as ALOFT-IPF Validates Mechanism; Price Target Unchanged at $17 Pending Further PIPE-791 Data
Premium
Ratings
Contineum: Hold Rating Reiterated as ALOFT-IPF Validates Mechanism; Price Target Unchanged at $17 Pending Further PIPE-791 Data
16h ago
CTNM
Contineum: Buy Rating Reaffirmed as Bristol Data De-Risk PIPE-791, Price Target Slightly Trimmed to $28
Premium
Ratings
Contineum: Buy Rating Reaffirmed as Bristol Data De-Risk PIPE-791, Price Target Slightly Trimmed to $28
21h ago
CTNM
Analyst Maintains Buy Rating on Contineum (CTNM) with Unchanged $23 Price Target, Citing Positive Readthrough from Bristol Myers Squibb’s ALOFT-IPF Trial
Premium
Ratings
Analyst Maintains Buy Rating on Contineum (CTNM) with Unchanged $23 Price Target, Citing Positive Readthrough from Bristol Myers Squibb’s ALOFT-IPF Trial
14d ago
CTNM
Analyst Maintains Buy on Contineum, Trims Price Target to $23 Following PIPE-307 Setback While PIPE-791 IPF Program Remains Core Value Driver
Premium
Ratings
Analyst Maintains Buy on Contineum, Trims Price Target to $23 Following PIPE-307 Setback While PIPE-791 IPF Program Remains Core Value Driver
29d ago
CTNM
Analyst Reaffirms Buy on Contineum, Highlighting PIPE-791 IPF Upside Despite Muscarinic MDD Trial Setback
Premium
Ratings
Analyst Reaffirms Buy on Contineum, Highlighting PIPE-791 IPF Upside Despite Muscarinic MDD Trial Setback
29d ago
CTNM
Contineum Therapeutics Reports Phase 2 MOONLIGHT-1 Results
Premium
Company Announcements
Contineum Therapeutics Reports Phase 2 MOONLIGHT-1 Results
29d ago
8K
CTNM
Contineum Therapeutics: Buy Rating Reiterated with PIPE-791 Upside Potential and Unchanged $26 Price Target
Premium
Ratings
Contineum Therapeutics: Buy Rating Reiterated with PIPE-791 Upside Potential and Unchanged $26 Price Target
1M ago
CTNM
More CTNM News >

CTNM News on the Web

Analyst Maintains Buy Rating on Contineum (CTNM) with Unchanged $23 Price Target, Citing Positive Readthrough from Bristol Myers Squibb’s ALOFT-IPF Trial
TipRanks News
Bullish
Contineum Therapeutics Inc trading halted, volatility trading pause
TipRanks News
Bearish
Contineum price target lowered to $17 from $18 at Morgan Stanley
TipRanks News
Neutral
Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from JonesTrading
TipRanks News
Bullish
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
Insider Monkey
Bearish
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX)
TipRanks News
Bullish
Contineum Therapeutics, Inc. at Morgan Stanley Global Healthcare Conference Transcript
GuruFocus News
Neutral
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
CTNM
Sector Average
Media Buzz
This Week1 articles
Weekly Average7.5 articles
News Sentiment
This Week50%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CTNM’s Media Buzz Sentiment?
1 articles about CTNM were published this week. In an average week, 7.5 articles are published.
    What is CTNM’s weekly average amount of articles?
    In an average week, 7.5 articles about CTNM are published.
      What is CTNM’s News Sentiment?
      50% of articles about CTNM were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        IQVIQVIA Holdings
        GILDGilead Sciences
        ABBVAbbVie
        VRTXVertex Pharmaceuticals
        NVSNovartis
        Showing the stocks with the most bullish news sentiment over the past week